mol42
26 Apr 2017
Tonight's presentation slides available prior to presentation tonight[link] getting better at not only affimers but keeping those who cannot attend up to speed!mol
mol42
25 Apr 2017
A Smith Interview 250417 [link]
mol42
24 Apr 2017
Moderna bit of info[link] virus...... hmmmanywayModerna has about $1.3 billion in cash on hand, according to Bancel. But with plans to spend more than $300 million a year investing in its technology, it will need to raise more money eventually. The most logical step would be to go public, and last year Moderna reorganized its business to prepare for an initial public offering.But at its current valuation, Moderna’s IPO would be the biggest in biotech history, leaving some investors scratching their heads as to how the company’s vaccine-heavy pipeline could justify such a number. If Moderna chooses to stay private, it’s unclear whether it can raise more cash without resorting to a dreaded down round, in which new shares are sold at a price below the last ones.more than enough for us to help them out!ok slightly tongue in cheek - lolbw allmol
mol42
24 Apr 2017
Re: Great news today twas only the 3rd April afterall that this was noted in interimsMultiple paid-for technology evaluations and collaborations now ongoing with
Four out of the top ten global large pharma and more than ten other biotech and pharma companieso Eight research tools companieso Several diagnostics companies including one of the top threeSeveral technology evaluations underway that could lead to the first reagents license deal during 2017.hopefully much more to come during the course of this calendar yearwe will see but a good startmol
mol42
24 Apr 2017
Re: Great news today somebody else must have thought so as well14:35:48 24-Apr-2017 80.50 50,000 40,250.00 Ordinary Trade - delayed publicationmol
paulmc1
24 Apr 2017
Great news today "We believe this deal is a key value inflection point for the company. " Let's hope so, interesting times indeed.
mol42
16 Apr 2017
Re: Capital Network Note update note[link]
mol42
14 Apr 2017
A Smith Interview 120417 Another interview[link]
Dyncaled
05 Apr 2017
Re: A Smith Interview 040417 mol Many thanks for all your postings. Interesting times ahead.
mol42
04 Apr 2017
A Smith Interview 040417 [link]
mol42
03 Apr 2017
Re: Interims bit more here[link] and genentech re avastin - i'll let you all google yourselvesmol
mol42
03 Apr 2017
Re: Interims bit here[link] longer than I anticipated but I'm looking forward to rest of 2017 and beyondmol
mol42
29 Mar 2017
Re: 3% shareholders as at 240317Current significant shareholders are as follows:IP Group plc – 24.8%Henderson Global Investors – 11.6%Aviva 9.7%Baillie Gifford & Co Limited – 7.2%Ruffer LLP – 7.1%Fidelity - 5.9%J O Hambro - 5.6%Fidelity 4.1%NFU - 3.5%As at 24th March 2017 the company has 68,386,857 ordinary shares of 10p each in issue.42.6% of the ordinary shares of the Company are not held in public hands.previouslyCurrent significant shareholders are as follows:IP Group plc – 24.8%Henderson Global Investors – 11.8%Aviva 9.7%Baillie Gifford & Co Limited – 7.6%Ruffer LLP – 7.1%J O Hambro - 4.7%Fidelity 4.1%NFU - 3.5%As at 24th November 2016 the company has 68,382,517 ordinary shares of 10p each in issue.42.6% of the ordinary shares of the Company are not held in public hands.mol
TheDrewster
21 Mar 2017
Re: Interims The biggest worry with news so imminent, is why the share price has drifted.Always worried "someone knows more than me"I have great hope of great things happening at AVCT which is why I have been adding through 2016.As ever, only time will tell how wise a move that was.
mol42
20 Mar 2017
Interims scheduled for 03/04/17probably the undernoted During coming weeks the company is expected to report on the next step in the pre-clinical development process: whether or not Affimer scaffolds are immunogenic. A positive outcome would be a low immune response rate.will be prior or in and around same timeanyway news coming very soonmol
